Dominik Paul Modest

[Filippo Pietrantonio @FilippoPietran4]

Health-related quality of life in patients with KRASG12C-mutated chemo... https://t.co/3sdekiViBw

[Dominik Paul Modest @ModestDominik]

@richardashcroft @NocturneLive Surprised by the joy
Hold on
Sonnet
On a beach
Life’s an ocean
Song for the lovers
Break the night
Beatitudes
Lucky man
They don’t own me
Lover
Love is noise
BSS

[GI CONNECT powered by COR2ED @giconnectInfo]

🚨 #LowerGIcancer highlights from #ASCO24 🚨

Prof. @JenSeligmann & Dr @ModestDominik share their views on new data from #COLLISION & #TRANSMET trials presented at the congress.

⬇️🎥⬇️

#MedEd #ASCOhighlights #CRCSM #LowerGI

[GI CONNECT powered by COR2ED @giconnectInfo]

🚨#LowerGIcancer highlights from #ASCO24🚨

Medical oncologists Prof. @JenSeligmann and Dr @ModestDominik share their views on new data in #rectalcancer and #CRC from the NEOPRISM-CRC trial & LBA3512.

Watch the video 📺 👇

#MedEd #oncology #CRCSM

[Myriam Chalabi @MyriamChalabi]

Voting open for @myESMO #president 2027-2028! Vote now, or on your way to #ASCO24! My vote 👇 @Prof_Nadia_H #mentor #strong #womenleaders #femalepresident

[NEJM @NEJM]

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) https://t.co/mLuAayTmTM

#ESMO23 #oncology

[Dominik Paul Modest @ModestDominik]

@YJanjigianMD @MSKCancerCenter @MSK_DeptOfMed @debschrag @OncoAlert Congrats to important study… a paradigm for patients sure to undergo surgery. Who are these patients? Or is TNT without surgery the way in these moderately advanced tumors the way? I find it more difficult than the NYT does 😂. I agree with the discussant it is an option…

[GI CONNECT powered by COR2ED @giconnectInfo]

Five @giconnectInfo experts provide a handy update from #ESMO2022!
➡️ Podcast Ep. 1: Lower #GIcancer highlights
➡️ Podcast Ep. 2: Upper #GIcancer highlights
➡️ Video summary of NICHE-2 trial
For the podcasts, video and downloadable content, follow: https://t.co/NOldiEyHaB
#MedEd

[Jenny Seligmann @JenSeligmann]

💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer
💥short duration safe pre-op
💥4% grade 3 events
💥100% R0 resection
💥95% major path; 67% pCR
…round of applause in session!
1/2

[Dominik Paul Modest @ModestDominik]

@alarjosan But promoting this without effect on DFS and OS… I am not up for it. Needs more effect for the overall population. Saying this as surgery-passionate oncologist

[Dominik Paul Modest @ModestDominik]

Great to see randomized data. Congratulations!! Great achievement. Final conclusion (do it or not) more complex. Data suggest that HIPEC influences local but not systemic control and systemic relapse is a frequent issue.

[Alvaro Arjona @alarjosan]

HIPECT4 shows that HIPEC with MMC in effective and safe to prevent peritoneal relapse in T4 colorectal cancer, presented in @myESMO 2022. @AndreaCercek @PSOGI_EC @ESSOnews @aecirujanos @_SEOM @indepso @ISSPP1 @HUReinaSofia @IMIBIC @SeguraJuanJ @operarelcancer @GECOP_ @PSugarbaker

[Dominik Paul Modest @ModestDominik]

Niche-2. No need for further interpretation… congrats to Myriam!! What a perfect presentation of a super trial. Great that we had a wowww moment in colon cancer.

[Ben Westphalen @BenWestphalen]

Well said @FilippoPietran4 …and @myESMO #ESMO22 is approaching fast!

[Kathrin Heinrich @heinrich_kat]

Proud to present our subgroup analysis of the PANAMA-study according to #gender and age in patients with #colorectalcancer at #ASCO2022! Thanks to my amazing mentors @ModestDominik and @StintzingS for their support!

[Nathanael Raschzok @nathanaelraschz]

The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer.
https://t.co/RQySqOYS7u
@ModestDominik
@Sauer_et_al

[Dominik Paul Modest @ModestDominik]

@JenSeligmann @MyriamChalabi Who was this? Always keen on learning what to avoid?

[Dominik Paul Modest @ModestDominik]

@MyriamChalabi @JenSeligmann Maybe you just need nicer reviewers😂

[GI CONNECT powered by COR2ED @giconnectInfo]

Our new podcast series is out! In Episode 2 @JenSeligmann, @McreeAutumn and @ModestDominik are discussing #immunotherapy approaches! Listen to the podcast and download the transcript at: https://t.co/jkF0NKqdMJ
#MedEd #GI #GC

[Charité - Universitätsmedizin Berlin @ChariteBerlin]

Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum https://t.co/ZBTGMlQgVb

[Dominik Paul Modest @ModestDominik]

@pashtoonkasi @realbowtiedoc @JenSeligmann @myESMO @OncoAlert I do hope that all options for local therapies were evaluated before random in Panama (consort diagram). Staying pragmatic: do maintenance if needed, switch to 2nd line afterwards…